JUL 23, 2022 2:08 PM PDT

Anti-inflammatory Compound Shows Promise in Treating Severe COVID-19

WRITTEN BY: Annie Lennon

An anti-inflammatory compound has shown promise in treating systemic inflammation and brain injury in patients with severe COVID-19. The corresponding study was published in Science Translational Medicine.

Hyperinflammation triggered by SARS-CoV-2 is a life-threatening condition and a major cause of disease severity in COVID-19. It involves the excessive activation of multiple immune pathways that can lead to tissue damage, acute respiratory distress syndrome (ARDS), and multi-organ failure. 

In the current study, researchers conducted a Phase 2a clinical study to see whether OP-101, an experimental anti-inflammatory nanotherapeutic, could treat hyper inflammation from COVID-19. To do so, they enrolled 24 patients classified as having 'severe' COVID-19 according to the World Health Organization's seven-point ordinal scale (WHO 7OS), and randomized them to receive either a placebo or different doses of OP-101. 

In the end, the researchers noted that OP-101 reduced inflammatory markers and markers of neurological injury more effectively than placebo treatments. They additionally found that whereas 71% of patients on the placebo required mechanical ventilation or died after 30 or 60 days of treatment, the same was true for just 18% of patients treated with OP-101. 

The researchers further found that 60 days post-treatment, whereas only 3 of 7 patients on placebos survived, the same was true for 14 of 17 patients treated with OP-101. 

"Although this was a small-dose escalation trial, there was clearly a strong signal toward benefit at both acute and chronic time point," said Aaron M. Gusdon, MD, assistant professor in the Vivian L. Smith Department of Neurosurgery with McGovern Medical School at UTHealth Houston, first author of the study.

"The possibility that this therapy could also benefit patients with other diseases that lead to systemic inflammatory responses, including various forms of brain injury, is extremely exciting," he added. 

The researchers note that while their findings are promising, their sample size was small, meaning that a larger study is needed to further evaluate the safety and efficacy of OP-101 in severe COVID-19. 

 

Sources: Science Daily, Science Translational Medicine

 

About the Author
University College London
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
JUL 21, 2022
Cell & Molecular Biology
'Junk' DNA May Stall Replication, Increasing Cancer Risk
JUL 21, 2022
'Junk' DNA May Stall Replication, Increasing Cancer Risk
Huge sections of the human genome are made up of highly repetitive sequences, areas where bases like ATATAT repeat in lo ...
AUG 27, 2022
Drug Discovery & Development
Universal Vaccine for Influenza A and B Shows Promise in Mice
AUG 27, 2022
Universal Vaccine for Influenza A and B Shows Promise in Mice
A new universal flu vaccine is effective against both influenza A and B viruses in mice. The corresponding study was pub ...
SEP 04, 2022
Drug Discovery & Development
Deep Brain Stimulation Shows Promise for Binge-Eating Disorder
SEP 04, 2022
Deep Brain Stimulation Shows Promise for Binge-Eating Disorder
Deep brain stimulation (DBS) may help control symptoms of binge-eating disorder and induce weight loss. The correspondin ...
SEP 20, 2022
Microbiology
Manuka Honey Helps Treat Drug Resistant Lung Infections
SEP 20, 2022
Manuka Honey Helps Treat Drug Resistant Lung Infections
Drug resistant bacterial infections are expected to increase, and these dangerous illnesses already claim the lives of t ...
OCT 05, 2022
Health & Medicine
Emergency Contraception Pills are Significantly Less Effective in People Who Are Overweight
OCT 05, 2022
Emergency Contraception Pills are Significantly Less Effective in People Who Are Overweight
Emergency contraception pills can be used to prevent pregnancy within 72 hours of having unprotected sex. When taken as ...
OCT 01, 2022
Drug Discovery & Development
Capsule-based Fecal Microbiota Transplant Treats Clostridiodes Difficile Infection
OCT 01, 2022
Capsule-based Fecal Microbiota Transplant Treats Clostridiodes Difficile Infection
Oral treatment with Fecal Microbiota Transplant (FMT) via capsules containing freeze-dried microbes has similar effects ...
Loading Comments...